Leading the way to new and better cancer treatments
About Polaris
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies.
Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others.
Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China.
Clinical Trials
Development and Manufacturing Capabilities
Company News
Polaris Group commenced the ground-breaking ceremony for Zhunan plant today with Chairman & CEO Dr. Hsu sharing the 5-year dual-engine accelerated growth strategy
2025/4/15-On April 15th, 2025, Polaris Group-KY (6550) held a groundbreaking ceremony for the new plant with the expansion of 6 production lines at Zhunan. The attending guests and the ones sending their congratulations include Hsinchu Science Park Bureau, Longtai Construction, Hua Nan Bank, Taiwan Cooperative Bank, Shanghai Commercial & Savings Bank, Anxo Pharmaceutical, and many representatives from different industries. Chairman and CEO of Polaris Group Dr. Steve Hsu gave a ceremonial speech, mentioning that Polaris plans to invest a total of approximately NT$8 billion in phases to expand production capacity over the next five years (2025-2029), with the goal of reaching an annual output value of NT$100 billion with the dual engines after the full expansion with loaded capacity. The dual engine model includes (1) ADI-PEG20 (trade name ADZODI) for (a) malignant pleural mesothelioma (lung mesothelioma, MPM), (b) glioblastoma (brain cancer, GBM), leiomyosarcoma (LMS), acute myeloid leukemia (AML), and other indications (2) GLP-1 generics for diabetes, weight loss, and other indications.
Polaris Group-KY (6550) Announces Subsidiary PPI Signed Exclusive Distribution Agreement with Er-Kim Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets
2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) signed a distribution agreement with Er-Kim Pharmaceuticals, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies. Polaris appointed Er-Kim as the exclusive partner to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region (Central & Eastern Europe, Eurasia, North Africa and Mediterranean regions).
Polaris Group-KY (6550) Announces Subsidiary PPI Signed Exclusive Partnership with Tabuk Pharmaceuticals to introduce ADI-PEG20 (ADZODI), an innovative First-in-Class arginine degradation innovative drug for hard-to-treat cancers in the Kingdom of Saudi Arabia and GCC Region
2025/4/14-Polaris Group-KY (6550) announces today its US California subsidiary Polaris Pharmaceuticals Inc. (PPI) signed an exclusive licensing agreement with Tabuk Pharmaceutical Manufacturing Company (a fully owned subsidiary of Astra Industrial Group, a listed company in Saudi Arabia) to introduce ADI-PEG20 (ADZODI), a novel treatment for Malignant Pleural Mesothelioma (MPM), to the 7 markets in Saudi Arabia and the GCC region. This partnership is set to improve the treatment landscape by delivering innovative therapeutic solution aimed at improving patient outcomes across the region.
Polaris Group-KY Successfully Completes 2024 Capital Injection to Accelerate Dual-Engine Core Strategy and Enhance Future Growth Momentum
2024/12/10-Polaris Group-KY announced that it has successfully completed its Year 2024 capital injection with fully raising NT$1,176 million and scheduling to list the newly issued shares on December 11, 2024. This successful capital injection received strong support from domestic and international investors, reflecting the market’s confidence in the company’s development prospects.